Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „respect“
Suchtreffer
Begriffe & Kennungen
CellCept · 4.5 · Sevelamer Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mof
Eintrag öffnenCellCept · 4.5 · Sevelamer Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mof
Eintrag öffnenCellCept · 4.5 · Sevelamer Decrease in MPA Cmax and AUC0-12h by 30% and 25%, respectively, were observed when mycophenolate mof
Eintrag öffnenCelsentri · 4.5 · Thus, CELSENTRI dose should be modified in line with the recommendation for co-administration with respective
Eintrag öffnenCelsentri · 4.5 · Thus, CELSENTRI dose should be modified in line with the recommendation for co-administration with respective
Eintrag öffnenCerdelga · 4.5 · 6 eliglustat 2.4- and 3.0-fold, respectively. Use of a moderate CYP3A inhibitor with eliglustat is not recomme
Eintrag öffnenCoagadex · 4.8 · For safety information with respect to transmissible agents, see section 4.4.
Eintrag öffnenDabigatran Etexilate Accord · 4.5 · 13 unchanged comparing combined treatment and the respective mono -treatments. With a loading dose of 300 mg o
Eintrag öffnenDabigatran Etexilate Accord · 4.5 · 85 increase the risk for any bleeding from 12 % to 18 % and 24 % with 81 mg and 325 mg ASA, respectively (see
Eintrag öffnenDarunavir Krka · 4.8 · During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective o
Eintrag öffnenDarunavir Krka · 4.8 · During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective o
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.8 · During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective o
Eintrag öffnenDarunavir Viatris (previously Darunavir Mylan) · 4.8 · During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective o
Eintrag öffnenDegevma · 4.8 · The cumulative incidence at one year was 1.1 % for denosumab and 0.6 % for zoledronic acid, respectively.
Eintrag öffnenDialeptic seizure
Eintrag öffnenDocetaxel Kabi · 4.8 · • 1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. • 25
Eintrag öffnenDocetaxel Kabi · 4.8 · • 1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. • 25
Eintrag öffnenDocetaxel Kabi · 4.8 · • 1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. • 25
Eintrag öffnenDocetaxel Kabi · 4.8 · • 1,312 and 121 patients who received 100 mg/m² and 75 mg/m² of docetaxel as a single agent respectively. • 25
Eintrag öffnenDynastat · 4.5 · Plasma exposure (AUC and Cmax) to valdecoxib was increased (38% and 24%, respectively) when coadministered wit
Eintrag öffnen